Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Open in Screener

WRAP

Wrap Technologies Inc

Jun 25 • 04:00PM ET

1.87

Dollar change -0.19
Percentage change -9.22	%

Technology • Scientific & Technical Instruments • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-0.37	Insider Own	36.65%	Shs Outstand	44.21M	Perf Week	40.60%
Market Cap	82.67M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	28.01M	Perf Month	14.72%
Income	-15.55M	PEG	-	EPS next Q	-	Inst Own	11.72%	Short Float	18.70%	Perf Quarter	-7.88%
Sales	9.13M	P/S	9.06	EPS this Y	-	Inst Trans	-5.75%	Short Ratio	19.74	Perf Half Y	-20.09%
Book/sh	0.43	P/B	4.37	EPS next Y	-	ROA	-48.44%	Short Interest	5.24M	Perf Year	32.62%
Cash/sh	0.34	P/C	5.54	EPS next 5Y	-	ROE	-61.54%	52W Range	1.21 - 7.01	Perf YTD	-39.68%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-60.64%	ROI	-75.19%	52W High	-73.32%	Beta	1.56
Dividend TTM	-	Quick Ratio	1.85	Sales past 5Y	-	Gross Margin	53.64%	52W Low	54.55%	ATR (14)	0.17
Dividend Ex-Date	-	Current Ratio	2.39	EPS Y/Y TTM	20.94%	Oper. Margin	-171.91%	RSI (14)	60.50	Volatility	18.72% 9.20%
Employees	-	Debt/Eq	0.01	Sales Y/Y TTM	32.02%	Profit Margin	-170.32%	Recom	3.00	Target Price	2.50
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	25.82%	Payout	-	Rel Volume	1.25	Prev Close	2.06
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	113.46%	Earnings	Mar 28 AMC	Avg Volume	265.29K	Price	1.87
SMA20	25.57%	SMA50	14.21%	SMA200	-21.76%	Trades		Volume	337,861	Change	-9.22%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-25-22	Downgrade	Maxim Group	Buy → Hold
May-03-21	Initiated	Ladenburg Thalmann	Buy	$26.50
Apr-15-21	Initiated	Maxim Group	Buy	$11

Jun-21-24 09:05AM	Wrap Technologies, Inc. Issues Letter to Shareholders (GlobeNewswire) +23.62%
May-24-24 01:29PM	Wrap Technologies Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1) (GlobeNewswire)
Apr-26-24 09:16AM	Wrap Technologies Announces Exciting New Distributor Agreement with Kokusai Security (GlobeNewswire)
Apr-19-24 05:28PM	Wrap Technologies Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1) (GlobeNewswire)
Apr-15-24 09:05AM	Wrap Technologies, Inc. Provides Update on Operations and Timing to Report Financial Results (GlobeNewswire)
09:05AM	Loading…
Apr-01-24 09:05AM	Wrap Technologies Launches WrapAI Suite of Artificial Intelligence-Powered Functionality for Intrensic BWC and DEMS (GlobeNewswire)
Mar-25-24 09:05AM	Wrap Technologies, Inc. to Schedule New Date for Issuance of Financial Results and Investor Conference Call for Q4 and FY 2023 (GlobeNewswire) -7.31%
Mar-07-24 09:05AM	Wrap Technologies, Inc. to Report Last Quarter 2023 Financial Results on Thursday, March 28, 2024 at 4:30 p.m. ET (GlobeNewswire)
Mar-05-24 09:05AM	Wrap Technologies Announces BolaWrap Full Deployment of Detroit Police Department's Mental Health Crisis Intervention Team (CIT) (GlobeNewswire)
Feb-08-24 09:05AM	Wrap Technologies, Inc. Announces Full Deployment of BolaWrap for Fairfax County Police Department (GlobeNewswire) +9.34%
Feb-05-24 09:05AM	Wrap Technologies, Inc. Positions for Scale with Manufacturing and Sales Expansion while Reducing Workforce by 30% (GlobeNewswire)
Jan-16-24 09:05AM	Wrap Technologies, Inc. Appoints Scot Cohen as Chief Executive Officer (GlobeNewswire)
Dec-27-23 09:05AM	Wrap Technologies, Inc. Announces Largest BolaWrap Order in Company History (GlobeNewswire) +12.35%
Dec-06-23 09:05AM	Wrap Technologies, Inc Unveils Cutting-Edge AI Functionality for Wrap Intrensic Body-Worn Camera Solution (GlobeNewswire) +7.69%
Nov-21-23 09:05AM	Wrap Technologies, Inc. Bolsters BolaWrap 150 Deployments, Promoting Safer Communities Nationwide (GlobeNewswire)
01:07PM	Loading…
Nov-10-23 01:07PM	Wrap Technologies, Inc. (NASDAQ:WRAP) Q3 2023 Earnings Call Transcript (Insider Monkey) +6.99%
Nov-09-23 04:05PM	Wrap Technologies, Inc. Reports Third Quarter 2023 Results and Record Quarterly Revenue (GlobeNewswire)
Nov-01-23 12:00PM	Giles Tipsword Joins Wrap Technologies as Senior Vice President of North American Sales (GlobeNewswire)
Oct-26-23 09:05AM	Wrap Technologies Announces New Solution to Help Safeguard Cities (GlobeNewswire)
Oct-24-23 09:05AM	Wrap Technologies, Inc. to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023 at 5:00 p.m. ET (GlobeNewswire)
Oct-16-23 09:05AM	Wrap Technologies Announces Appointment of New Directors to the Board (GlobeNewswire) +9.29%
Oct-13-23 09:05AM	Wrap Technologies Launches Nationwide Don't Hurt Those Already Hurting Campaign (GlobeNewswire)
Oct-05-23 09:05AM	Wrap Technologies Announces Sponsorship of Nationwide Faith & Blue Weekend, October 6-9, 2023 (GlobeNewswire)
Sep-28-23 04:05PM	Wrap Technologies Announces International Expansion of BolaWrap 150 Remote Restraint Devices Across Italy (GlobeNewswire)
Sep-15-23 10:00AM	Wrap Technologies Announces Deployment of BolaWrap 150® Remote Restraint Devices Across Cobb County, Georgia (GlobeNewswire)
Aug-31-23 09:05PM	Wrap Technologies Unveils Critical Incident Management Virtual Reality Training Scenario for High-Stress Law Enforcement Environments (GlobeNewswire) +8.33%
Aug-09-23 04:05PM	Wrap Technologies, Inc. Reports Second Quarter 2023 Results and Major Acquisition (GlobeNewswire)
Aug-03-23 09:05AM	Wrap Technologies, Inc. Expands Virtual Reality Law Enforcement Training with New Immersive Scenarios (GlobeNewswire)
Jul-27-23 09:05AM	Law Enforcement Adopts BolaWrap Solution: Advancing Safer Outcomes with Opioid Settlement Funds (GlobeNewswire)
Jul-26-23 09:05AM	Wrap Technologies, Inc. to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023 at 5:00 p.m. ET (GlobeNewswire)
09:05AM	Loading…
Jul-20-23 09:05AM	Law Enforcement Agencies Embracing Technology Advancements With Wrap Technologies BolaWrap® 150 (GlobeNewswire)
Jul-13-23 09:05AM	Wrap Technologies Applauds Hillsborough County Sheriff's Office for Successful Utilization of BolaWrap Device (GlobeNewswire) +5.30%
Jul-06-23 12:10PM	Wrap Technologies, Inc. Announces the Closing of a $10 Million Offering to Fuel Growth (GlobeNewswire)
Jun-30-23 08:05AM	WRAP Technologies, Inc. Announces $10 Million Offering (GlobeNewswire)
Jun-27-23 09:05AM	Wrap Reality Exceeds 2022's Total Sales in Just Six Months, Revolutionizing Immersive Learning Experiences for Law Enforcement (GlobeNewswire) +6.77%
Jun-15-23 09:05AM	Wrap Technologies Builds Momentum as US Law Enforcement Agencies Embrace Innovative BolaWrap® Restraint Solution (GlobeNewswire) +5.65%
Jun-07-23 09:05AM	Wrap Technologies Launches Strategic Initiative to Enhance Campus Safety with BolaWrap® Amid Rising Mental Health Concerns; Showcasing at IACLEA Conference (GlobeNewswire)
Jun-01-23 09:05AM	Wrap Technologies to Showcase Its BolaWrap® Solution at the Public Risk Management Association (PRIMA) Conference (GlobeNewswire)
May-30-23 09:05AM	Wrap Technologies to Showcase Its Pioneering Virtual Reality Training Platform, Wrap Reality, at the International Counterterrorism Conference (GlobeNewswire)
May-26-23 02:30PM	Wrap Technologies, Inc. Welcomes Kevin Mullins as New CEO Spearheading Next-generation Public Safety Solutions for a Rapidly Evolving World (GlobeNewswire)
May-10-23 04:05PM	Wrap Technologies, Inc. Reports First Quarter 2023 Results (GlobeNewswire)
May-03-23 08:15AM	Wrap Technologies Announces Sponsorship of the Professional Networking Symposium Event at the Professionalizing Law Enforcement Community Engagement Training (PLECET) National Conference (GlobeNewswire)
Apr-26-23 08:15AM	Wrap Technologies, Inc. to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023 at 5:00 p.m. ET (GlobeNewswire) +7.69%
Apr-17-23 05:00PM	Wrap Technologies Announces CEO Change and Preliminary Estimated Financial Results for Q1 2023 (GlobeNewswire) -9.06% -7.38%
Mar-17-23 08:15AM	Wrap® to Host Investor Insights Webcast on March 23, 2023 (GlobeNewswire)
Mar-01-23 04:05PM	Wrap Technologies, Inc. Reports Fourth Quarter and Full Year 2022 Results (GlobeNewswire) -10.96%
Feb-15-23 08:15AM	Wrap Technologies, Inc. to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 1, 2023 at 5:00 p.m. ET (GlobeNewswire)
Feb-14-23 08:15AM	Officers Successfully Deploy BolaWrap® to Safely Apprehend Suspect Involved in a Domestic Dispute in Alton, TX (GlobeNewswire)
Feb-08-23 08:15AM	Wrap® Launches Use of Force Reduction Guarantee (GlobeNewswire) +6.82%
Feb-07-23 08:15AM	Wrap® to Host Investor Insights Webcast (GlobeNewswire) -9.47%
Jan-31-23 04:05PM	Officers Successfully Deploy BolaWrap® to Safely Take Into Protective Custody Someone Experiencing an Apparent Behavioral Health Crisis in Columbia, Missouri (GlobeNewswire) +17.27%
08:15AM	Wrap Technologies to Host an Investor Webinar (GlobeNewswire)
Jan-19-23 08:15AM	Wrap Technologies to Present at Lake Streets Take Aim Conference (GlobeNewswire)
Jan-11-23 08:15AM	Wrap Technologies Announces Full Deployment of BolaWrap 150® Remote Restraint Devices Across Montgomery County, Texas (GlobeNewswire)
Nov-30-22 09:05AM	Wrap Announces Technology Acquisition and Partnership with Lumeto, Inc. to Expand its Wrap Reality Training Platform (GlobeNewswire) -8.44%
Nov-12-22 07:22AM	Wrap Technologies Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-09-22 04:05PM	Wrap Technologies, Inc. Reports Third Quarter 2022 Results (GlobeNewswire) +11.89%
04:03PM	Wrap Announces New International Sales in South America and EMEA Regions (GlobeNewswire)
Oct-26-22 09:05AM	Wrap Technologies, Inc. to Report Third Quarter 2022 Financial Results on Wednesday, November 9, 2022 at 5:00 p.m. ET (GlobeNewswire)
Oct-13-22 09:05AM	Wrap Launches Wrap Reality ADAPT, a New Module to Its Current Virtual Reality Law Enforcement and Corrections Training Platform (GlobeNewswire)
Sep-20-22 04:05PM	Officers Successfully Deploy BolaWrap to Help Restrain Subject Having a Mental Health Crisis in LaGrange, Georgia (GlobeNewswire) -5.10%
Sep-14-22 09:05AM	New Body Cam Footage Presents Successful Use of BolaWrap in Georgia to Help De-escalate Crisis Situation (GlobeNewswire)
Aug-24-22 09:05AM	Wrap Announces Extension of LAPD BolaWrap Pilot Program (GlobeNewswire) +9.28%
Aug-11-22 01:27PM	Top Penny Stocks for August 2022 (Investopedia) +10.33%
Aug-10-22 04:02PM	Wrap Announces New International Sale of BolaWrap 150 in the Middle East (GlobeNewswire)
04:01PM	Wrap Technologies Reports Second Quarter 2022 Results (GlobeNewswire)
Jul-29-22 09:05AM	New Body Cam Footage Presents Successful Use of BolaWrap in Oregon (GlobeNewswire)
Jul-28-22 09:10AM	Wrap Technologies, Inc. Announces Release Date for Second Quarter 2022 Results (GlobeNewswire)
Jul-25-22 09:05AM	Wrap Announces the Appointment of New CFO Chris DeAlmeida (GlobeNewswire) -6.19%
Jul-21-22 08:57AM	Wrap Announces Sale of Wrap Reality Societal Reentry Enterprise Platform (GlobeNewswire)
Jul-19-22 09:07AM	Wrap Shares Body Cam Footage of Successful Prevention of Escalation with BolaWrap 150 Deployment on a Call to a Subject with a Knife (GlobeNewswire) +5.32%
Jul-06-22 09:03AM	Wrap Announces First Sale of Wrap Reality Inmate Societal Reentry Software (GlobeNewswire)
Jun-28-22 09:05AM	Wrap Shares New Body Cam Footage Demonstrating Successful Deployment of BolaWrap (GlobeNewswire) -11.54%
Jun-23-22 09:48AM	We Think Wrap Technologies (NASDAQ:WRAP) Needs To Drive Business Growth Carefully (Simply Wall St.)
Jun-22-22 11:00AM	WRAP to Hold Virtual 2022 Annual Meeting of Stockholders (GlobeNewswire)
Jun-15-22 09:04AM	Wrap Announces Endorsement from the National De-escalation Training Center for its BolaWrap Technology (GlobeNewswire)
Jun-07-22 08:52AM	Wrap Appoints Sales Executive Carlos Casas as VP of Sales & Marketing (GlobeNewswire) +6.60%
May-26-22 08:52AM	Wrap Technologies to Present at LD Micro by SRAX Invitational XII Investor Conference (GlobeNewswire) -7.88%
May-23-22 08:52AM	Wrap Announces Five Year Subscription Sale of Wrap Reality Virtual Reality Training Software (GlobeNewswire) +7.66%
May-09-22 09:07AM	Wrap Technologies (NASDAQ:WRAP) shareholders have endured a 63% loss from investing in the stock three years ago (Simply Wall St.)
May-03-22 04:01PM	Wrap Technologies Reports First Quarter 2022 Results (GlobeNewswire)
Apr-25-22 10:30AM	Wrap Technologies, Inc. Announces Release Date for First Quarter 2022 Results (GlobeNewswire) -7.84%
08:50AM	Wrap Technologies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-18-22 09:00AM	Wrap Technologies expands Tempe leadership team with new president, CEO (American City Business Journals) +13.33%
09:00AM	Wrap Technologies Appoints TJ Kennedy as CEO and Kevin Mullins as President (Business Wire)
Mar-23-22 01:15PM	Wrap Technologies to Participate in the 2022 Virtual Growth Conference by Maxim Group LLC on March 28-30, 2022 (GlobeNewswire) +6.25%
Mar-21-22 05:01PM	Do Institutions Own Wrap Technologies, Inc. (NASDAQ:WRAP) Shares? (Simply Wall St.)
Mar-10-22 04:02PM	Wrap Technologies Reports Fourth Quarter and Full-Year 2021 Results (GlobeNewswire) -7.54%
Mar-08-22 12:57PM	Wrap Technologies to Present at the 34th Annual Roth Conference on March 13-15, 2022 (GlobeNewswire)
Mar-01-22 09:04AM	Wrap Technologies Announces Release Date for Fourth Quarter and Full Year Fiscal 2021 Results (GlobeNewswire)
Jan-31-22 09:12AM	WRAP Receives Largest Subscription Order to Date for its WRAP Reality Virtual Training Platform (GlobeNewswire) +12.13%
Jan-24-22 08:00AM	Wrap Technologies Announces Leadership Transition Plan to Support Next Phase of Corporate Strategy (Business Wire) -39.29%
Jan-20-22 09:47AM	WRAP Releases New Body Cam Video Deployment of BolaWrap in Pembroke Pines, Florida (GlobeNewswire)
Jan-19-22 09:18AM	Wrap Technologies to Present at Take Aim: Lake Streets Shooting Sports and Public Safety Event on January 26, 2022 (GlobeNewswire)
Jan-13-22 09:08AM	Edenton Police Department Hosts Wrap Reality Virtual Training Platform Demonstrations for its Neighboring Law Enforcement Agencies (GlobeNewswire) -6.68%
Jan-11-22 09:47AM	Body Cam Video Demonstrates Successful Double Deployment of BolaWrap to Safely Restrain Disruptive Subject (GlobeNewswire) +5.54%
Jan-10-22 09:17AM	WRAP Receives First Order Through the Arizona Municipal Risk Retention Pool Funding Program (GlobeNewswire)
Jan-06-22 09:03AM	Wrap Technologies to Present at the Needham Virtual Growth Conference on January 11 (GlobeNewswire)
Jan-05-22 09:12AM	WRAP Announces International Sale of 15,000 Cartridges for its BolaWrap Remote Restraint Device (GlobeNewswire)
Jan-04-22 09:48AM	WRAP Announces Reorder of Next Generation BolaWrap 150 by the Dominican Republic Ministry of Defense (GlobeNewswire)

Wrap Technologies, Inc. is a global public safety technology and service company, which engages in the provision of modern policing solutions to law enforcement and security personnel. Its products include BolaWrap Remote Restraint Device and Wrap Reality. The company was founded by Elwood G. Norris, Scot J. Cohen, and James A. Barnes in March 2016 and is headquartered in Tempe, AZ.

Open in Screener

PTPI

Petros Pharmaceuticals Inc

Jun 25 • 04:00PM ET

0.4800

Dollar change +0.0350
Percentage change 7.87	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Index	-	P/E	-	EPS (ttm)	-6.21	Insider Own	12.51%	Shs Outstand	7.00M	Perf Week	14.29%
Market Cap	3.36M	Forward P/E	-	EPS next Y	-3.26	Insider Trans	0.00%	Shs Float	6.12M	Perf Month	-21.76%
Income	-13.04M	PEG	-	EPS next Q	-	Inst Own	0.92%	Short Float	2.53%	Perf Quarter	-69.43%
Sales	6.98M	P/S	0.48	EPS this Y	38.07%	Inst Trans	0.74%	Short Ratio	0.35	Perf Half Y	-65.96%
Book/sh	1.42	P/B	0.34	EPS next Y	19.51%	ROA	-33.16%	Short Interest	0.15M	Perf Year	-76.00%
Cash/sh	1.58	P/C	0.30	EPS next 5Y	-	ROE	-91.54%	52W Range	0.38 - 4.74	Perf YTD	-65.96%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-76.03%	52W High	-89.87%	Beta	2.33
Dividend TTM	-	Quick Ratio	1.46	Sales past 5Y	-14.44%	Gross Margin	17.66%	52W Low	24.68%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	1.60	EPS Y/Y TTM	-	Oper. Margin	-140.66%	RSI (14)	44.40	Volatility	9.27% 12.47%
Employees	21	Debt/Eq	0.75	Sales Y/Y TTM	-	Profit Margin	-186.72%	Recom	1.00	Target Price	4.00
Option/Short	No / Yes	LT Debt/Eq	0.60	EPS Q/Q	17.02%	Payout	-	Rel Volume	5.15	Prev Close	0.44
Sales Surprise	-121.14%	EPS Surprise	-125.23%	Sales Q/Q	74.01%	Earnings	Feb 28	Avg Volume	445.16K	Price	0.48
SMA20	-3.80%	SMA50	-19.26%	SMA200	-60.71%	Trades		Volume	2,183,190	Change	7.87%

May-29-24 09:00AM	Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch (ACCESSWIRE)
May-21-24 09:15AM	Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA (ACCESSWIRE)
May-16-24 10:53AM	PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) +6.30%
May-14-24 09:15AM	Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe (ACCESSWIRE)
07:00AM	Lemonaid Health Now Offers Prescription ED Medication STENDRA Through Collaboration with Petros Pharmaceuticals (GlobeNewswire)
10:20AM	Loading…
Apr-25-24 10:20AM	Petros Pharmaceuticals announces online distribution for lead ED product with Lemonaid Health (News Direct)
Apr-23-24 09:15AM	Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health (ACCESSWIRE)
Apr-16-24 09:15AM	Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil) (ACCESSWIRE) -9.97%
Apr-02-24 09:53AM	PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -23.57%
09:15AM	Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status (ACCESSWIRE)
Mar-19-24 09:00AM	Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider (ACCESSWIRE)
Mar-11-24 07:00AM	BestGrowthStocks.Com Issues Comprehensive Analysis of Petros Pharmaceuticals Inc (News Direct)
Feb-14-24 09:15AM	Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider (ACCESSWIRE)
Jan-24-24 09:15AM	Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch (ACCESSWIRE) -8.00%
Jan-17-24 09:00AM	Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC Switch (ACCESSWIRE)
10:00AM	Loading…
Dec-12-23 10:00AM	Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status (ACCESSWIRE) +7.33%
09:15AM	Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestors (rosuvastatin) OTC Switch Technology Provider (ACCESSWIRE)
Dec-05-23 09:15AM	Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's (rosuvastatin) OTC Switch Technology Provider (ACCESSWIRE)
Oct-30-23 09:15AM	Petros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R) (ACCESSWIRE)
Oct-19-23 09:00AM	Following Encouraging FDA Feedback Petros Pharmaceuticals Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRA (ACCESSWIRE)
Oct-04-23 09:00AM	Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential OTC STENDRA Label (ACCESSWIRE) -8.82%
Sep-28-23 08:00AM	Petros Pharmaceuticals to Present at the LD Micro Main Event XVI (ACCESSWIRE)
Sep-11-23 09:00AM	Petros Pharmaceuticals Provides Letter to Shareholders (ACCESSWIRE) +6.21%
Sep-06-23 04:05PM	Petros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference (ACCESSWIRE)
Jul-13-23 04:30PM	Petros Pharmaceuticals Announces Capital Raise of $15 Million (ACCESSWIRE) -6.60% -10.03%
Nov-30-22 12:45PM	Petros Pharmaceuticals Announces Reverse Stock Split (ACCESSWIRE)
Nov-15-22 08:00AM	Petros Pharmaceuticals Reports Third Quarter 2022 Financial Results and Corporate Update (ACCESSWIRE)
Oct-25-22 09:00AM	New FDA-Approved Labeling for Petros Pharmaceuticals STENDRA (avanafil) Now Includes Efficacy Data Regarding Use in Men Who Have Undergone Radical Prostatectomy (ACCESSWIRE) +38.81%
Oct-21-22 08:00AM	Petros Pharmaceuticals to Participate in Two October 2022 Conferences (ACCESSWIRE)
Aug-15-22 08:00AM	Petros Pharmaceuticals Reports Record Revenue and Gross Profit During Second Quarter 2022 (ACCESSWIRE)
10:27AM	Loading…
Jul-28-22 10:27AM	Petros Pharmaceuticals Responds to Fraudulent Press Release (GlobeNewswire)
09:25AM	Petros Pharmaceuticals to be Acquired by Henry Crown and Company for $3.25 per share (GlobeNewswire)
Jul-19-22 09:15AM	Petros Pharmaceuticals Kicks Off Social Media Campaign with Celebrity Physician Dr. Drew Pinsky (GlobeNewswire)
May-16-22 05:00PM	Petros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-03-22 09:23AM	Petros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Companys Novel Topical Investigational Treatment for Peyronies Disease Which Impacts More Than 1 in 10 Men in the US (GlobeNewswire) +7.21%
Apr-27-22 09:25PM	Petros Pharmaceuticals to Present at the Planet MicroCap Showcase 2022 (GlobeNewswire)
09:00AM	Keynotes, Educational Panels and 88 Companies to Present at the Planet MicroCap Showcase on May 3-5, 2022 at Bally's Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
Apr-26-22 09:15AM	Petros Pharmaceuticals, Inc. Engages Massachusetts General Hospital in a Sponsored Research Agreement for Tissue-Specific Oxygenation Sensor Technology (GlobeNewswire) -10.24%
Apr-19-22 09:15AM	Petros Pharmaceuticals Announces Positive Results of Over-the-Counter (OTC) Label Comprehension Study for Erectile Dysfunction Drug STENDRA (avanafil) (GlobeNewswire) +20.91%
Apr-01-22 07:00AM	Petros Pharmaceuticals Reports Year End 2021 Financial Results and Corporate Highlights (GlobeNewswire) -6.41%
Mar-03-22 08:00AM	Petros Pharmaceuticals to Present at the Q1 Investor Summit Conference (GlobeNewswire)
Feb-01-22 09:15AM	Petros Pharmaceuticals Partners with Celebrity Physician Dr. Drew to Bring Awareness to Men's Health (PR Newswire)
Jan-24-22 09:15AM	Petros Pharmaceuticals Partners with Leading Global Contract Manufacturer to Bring Production of Erectile Dysfunction Drug STENDRAÒ (avanafil) to the United States (PR Newswire) +10.60%
Jan-18-22 09:20AM	Petros Pharmaceuticals Launches Two Self-Selection Studies for Erectile Dysfunction Drug STENDRA® (avanafil) (PR Newswire) -11.45%
Jan-06-22 04:30PM	Petros Pharmaceuticals to Present at the H.C. Wainwright Bioconnect 2022 Virtual Conference and the Biotech Showcase 2022 (PR Newswire)
Jan-05-22 01:38PM	Neville Rodie & Shaw Inc Buys Cleveland-Cliffs Inc, Palo Alto Networks Inc, Novo Nordisk ... (GuruFocus.com) -9.15%
Dec-28-21 09:15AM	Petros Pharmaceuticals Announces Closing of $7.5 Million Offering (PR Newswire) +9.27%
Dec-22-21 09:10AM	Petros Pharmaceuticals Announces $7.5 Million Offering (PR Newswire) -18.34%
Dec-08-21 09:15AM	Petros Pharmaceuticals Announces Positive Over-the-Counter (OTC) Label Comprehension Study Results for Erectile Dysfunction Drug STENDRA® (avanafil) (PR Newswire) +7.69%
Dec-02-21 12:00PM	Petros Pharmaceuticals Announces Closing of $10 Million Offering (PR Newswire) +10.68%
Nov-30-21 09:00AM	Petros Pharmaceuticals Announces $10 Million Offering (PR Newswire) -28.50%
Nov-15-21 04:30PM	Petros Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update (PR Newswire) -22.02%
Nov-11-21 09:15AM	Petros Pharmaceuticals to Present at the Q4 Investor Summit Conference (PR Newswire)
Nov-08-21 09:15AM	Petros Pharmaceuticals Expands Program for Novel Investigational Non-Invasive Treatment Formulation for Peyronie's Disease (PR Newswire)
Nov-03-21 09:16AM	Petros Pharmaceuticals, Inc. Through Exclusive Marketing Agreement with Hims & Hers Health, Inc. Generates 476% Year-Over-Year Growth of STENDRA Tablet Sales (PR Newswire) +64.57%
Oct-21-21 09:25AM	Petros Pharmaceuticals to Participate at Upcoming Benzinga Conference and Interview Show (PR Newswire)
Oct-19-21 09:25AM	Petros Pharmaceuticals Announces Closing of $5.7 Million Registered Direct Offering (PR Newswire)
Oct-14-21 09:00AM	Petros Pharmaceuticals Announces $5.7 Million Registered Direct Offering (PR Newswire)
Sep-23-21 08:30AM	Petros Pharmaceuticals to Present at the Benzinga Healthcare Small Cap Conference (PR Newswire)
Sep-10-21 08:30AM	Petros Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (PR Newswire)
Aug-17-21 09:25AM	Petros Pharmaceuticals Announces Second Quarter Financial Results and Provides Corporate Update; Reports a 123% Increase in Year Over Year Quarterly STENDRA® (avanafil) Net Sales (PR Newswire) -7.75%
Aug-16-21 08:30AM	Keynotes, Educational Panels and 60 Companies to Present at the SNN Network Summer Virtual Event on August 17-19, 2021 (ACCESSWIRE) -10.26%
Aug-12-21 08:00AM	Petros Pharmaceuticals to Present at Two Upcoming August Conferences (PR Newswire)
Aug-11-21 10:39AM	Petros Pharmaceuticals: Invitation to the Q3 Virtual Investor Summit (Newsfile)
Jul-27-21 09:25AM	FDA Grants Meeting to Petros Pharmaceuticals to Discuss Label Expansion of Erectile Dysfunction Drug STENDRA® (PR Newswire)
Jul-13-21 09:15AM	Petros Pharmaceuticals Completes Pilot Label Comprehension Study to Initiate Process for Stendra® Prescription Erectile Dysfunction Medication to Achieve Designation as an Over-the-Counter Treatment (PR Newswire)
Jul-12-21 08:15AM	Petros Pharmaceuticals to Present at the Access to Giving Virtual Investor Conference on July 14, 2021 (PR Newswire)
Jun-02-21 10:12AM	Petros Pharmaceuticals to Present at the LD Micro Virtual Invitational Conference on June 10, 2021 (PR Newswire)
May-17-21 08:22AM	Petros Pharmaceuticals Announces First Quarter Financial Results and Provides Corporate Update; Reports 300% increase in Year-Over-Year STENDRA Net Sales (PR Newswire) +5.74%
May-14-21 08:30AM	Petros Pharmaceuticals to Participate at the Investor Summit Conference and Present to Investors on May 18, 2021 (PR Newswire)
May-07-21 08:00AM	Petros Pharmaceuticals to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 13, 2021 (PR Newswire) +5.59%
Mar-18-21 09:00AM	Recently Published Research on Stendra®(avanafil) for Endothelial Function in Men with Erectile Dysfunction to Initiate Petros Pharmaceuticals' Plans for Expanded Labeling (PR Newswire)
Feb-18-21 08:00AM	Petros Pharmaceuticals Welcomes Dr. Mohit Khera to Steering Committee to Expand into Non-Rx Status for Stendra® (avanafil) (PR Newswire) -9.22%
Feb-04-21 08:30AM	Petros Pharmaceuticals Establishes Steering Committee to Expand into Non-Rx Status for Stendra® (avanafil) (PR Newswire)
Jan-19-21 08:00AM	Petros Pharmaceuticals to Participate in NobleCon17 (GlobeNewswire)
Dec-08-20 04:15PM	Neurotrope, Inc. Completes Independent Spin-off of Neurotrope Bioscience, Inc. and is Renamed Synaptogenix, Inc. (PR Newswire)

Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, a FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.

Open in Screener

SNPX

Synaptogenix Inc

Jun 25 • 04:00PM ET

4.33

Dollar change -0.14
Percentage change -3.13	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Index	-	P/E	-	EPS (ttm)	-37.21	Insider Own	2.14%	Shs Outstand	1.23M	Perf Week	-0.46%
Market Cap	5.33M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.21M	Perf Month	-7.48%
Income	-12.23M	PEG	-	EPS next Q	-	Inst Own	3.97%	Short Float	1.75%	Perf Quarter	-5.27%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-62.35%	Short Ratio	0.39	Perf Half Y	-35.85%
Book/sh	20.32	P/B	0.21	EPS next Y	-	ROA	-13.75%	Short Interest	0.02M	Perf Year	-80.21%
Cash/sh	22.98	P/C	0.19	EPS next 5Y	-	ROE	-16.94%	52W Range	3.53 - 47.00	Perf YTD	-36.30%
Dividend Est.	-	P/FCF	-	EPS past 5Y	8.59%	ROI	-55.44%	52W High	-90.79%	Beta	1.47
Dividend TTM	-	Quick Ratio	4.58	Sales past 5Y	0.00%	Gross Margin	-	52W Low	22.75%	ATR (14)	0.31
Dividend Ex-Date	-	Current Ratio	4.58	EPS Y/Y TTM	-145.64%	Oper. Margin	0.00%	RSI (14)	46.93	Volatility	6.94% 6.22%
Employees	8	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	3.00	Target Price	350.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	93.78%	Payout	-	Rel Volume	6.33	Prev Close	4.47
Sales Surprise	-	EPS Surprise	21.82%	Sales Q/Q	-	Earnings	-	Avg Volume	54.24K	Price	4.33
SMA20	-0.88%	SMA50	-4.83%	SMA200	-27.16%	Trades		Volume	314,905	Change	-3.13%

May-20-24 11:54AM	SNPX Stock Earnings: Synaptogenix Reported Results for Q1 2024 (InvestorPlace)
May-07-24 09:00AM	Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery (PR Newswire)
Apr-24-24 09:15AM	Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing (PR Newswire)
Apr-09-24 09:15AM	Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics (PR Newswire) -8.35%
Apr-03-24 08:00AM	Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing (PR Newswire)
09:00AM	Loading…
Dec-19-23 09:00AM	Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders (PR Newswire) +5.45%
Dec-06-23 09:00AM	Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's (PR Newswire)
Nov-02-23 09:00AM	Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology (PR Newswire)
Sep-26-23 09:00AM	Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease (PR Newswire) +5.67%
Sep-07-23 09:00AM	Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study (PR Newswire) -12.23%
Jul-19-23 09:00AM	Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis (PR Newswire)
Jul-13-23 09:00AM	Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience (PR Newswire) +20.79%
Mar-07-23 09:00AM	Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities (PR Newswire)
Dec-16-22 09:00AM	Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease (PR Newswire) -74.63%
Nov-18-22 09:00AM	Synaptogenix Announces $15 Million Private Placement with Existing Investors (PR Newswire) +12.72%
09:00AM	Loading…
Oct-19-22 09:00AM	Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022 (PR Newswire)
Sep-28-22 11:50AM	Synaptogenix Welcomes Lecanemab Phase 3 Trial Results (PR Newswire)
Aug-12-22 09:00AM	Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network (PR Newswire) +5.10%
Jul-26-22 09:15AM	Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data (PR Newswire) +6.37%
Jul-21-22 09:15AM	Synaptogenix Announces Corporate Update Conference Call (PR Newswire)
Jul-20-22 09:15AM	Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data (PR Newswire) +5.81%
May-17-22 09:15AM	Synaptogenix to Present at the Cell Symposium (PR Newswire) +10.97%
Apr-19-22 09:15AM	Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial (PR Newswire) -5.69%
Apr-05-22 09:15AM	New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease (PR Newswire)
Mar-29-22 09:15AM	Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit (PR Newswire)
Mar-22-22 09:15AM	Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum (PR Newswire)
Mar-15-22 09:15AM	Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022) (PR Newswire)
Feb-23-22 09:15AM	Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis (PR Newswire)
Feb-07-22 09:38AM	Orion Capital Management LLC Buys Qualcomm Inc, Distillate U.S. ... (GuruFocus.com) -5.88%
Feb-01-22 09:15AM	Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients (PR Newswire) +29.36%
11:58AM	Loading…
Dec-06-21 11:58AM	We're Hopeful That Synaptogenix (NASDAQ:SNPX) Will Use Its Cash Wisely (Simply Wall St.)
Sep-28-21 09:00AM	Synaptogenix Announces Participation at the Benzinga Healthcare Small Cap Conference (PR Newswire)
Sep-10-21 09:00AM	Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference (PR Newswire)
Aug-05-21 10:00AM	Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome (PR Newswire) -6.18%
Jul-26-21 09:15AM	Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021 (PR Newswire) -19.09%
Jul-21-21 09:00AM	Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings (PR Newswire) +19.86%
Jul-14-21 09:00AM	Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline (PR Newswire) +9.74%
Jul-07-21 09:00AM	Synaptogenix Announces Regenerative Patent Award to Treat Alzheimer's Disease (PR Newswire) -13.16%
Jun-24-21 09:00AM	Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network (PR Newswire)
Jun-14-21 09:00AM	Synaptogenix Announces $12.5 Million Private Placement (PR Newswire)
Jun-09-21 09:00AM	Synaptogenix Announces Phase 2b NIH Sponsored Alzheimer's Disease Trial Update (PR Newswire)
05:38AM	Is Synaptogenix (NASDAQ:SNPX) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
May-19-21 09:00AM	Synaptogenix Announces Plan to Uplist on the Nasdaq Stock Market (PR Newswire)
May-10-21 09:00AM	Synaptogenix, Inc: Invitation to the Benzinga Global Small Cap Conference (Newsfile) -12.50%
Apr-26-21 09:00AM	Synaptogenix to Present at Sachs 4th Annual Neuroscience Innovation Forum (PR Newswire) +7.60%
Apr-01-21 09:00AM	Synaptogenix Announces Phase 2b Bryostatin-1 Clinical Trial Update (PR Newswire)
Mar-05-21 09:00AM	Synaptogenix to Present at the H.C. Wainwright Global Life Sciences Conference (PR Newswire) -8.16%
Feb-25-21 09:12AM	Synaptogenix to Present at Upcoming Scientific Industry Conferences (PR Newswire)
Feb-12-21 09:00AM	Synaptogenix to Participate in the Winter Wonderland - Best Ideas from the Buy-Side Conference (PR Newswire)
Feb-09-21 09:00AM	Synaptogenix Files Application to List on the Nasdaq Stock Market (PR Newswire) +20.83%

Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of Bryostatin and Platform Drug used for the treatment of Alzheimer's disease, Fragile X Syndrome or Autism, Multiple Sclerosis, Parkinson's Disease, Traumatic Brain Injury, and Stroke. The company was founded on October 31, 2012 and is headquartered in New York, NY.

Open in Screener

XWEL

XWELL Inc

Jun 25 • 04:00PM ET

1.67

Dollar change +0.01
Percentage change 0.60	%

Healthcare • Diagnostics & Research • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VXF VTI

Index	-	P/E	-	EPS (ttm)	-5.93	Insider Own	11.36%	Shs Outstand	4.18M	Perf Week	-28.94%
Market Cap	6.98M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	3.71M	Perf Month	3.09%
Income	-24.74M	PEG	-	EPS next Q	-	Inst Own	7.20%	Short Float	1.72%	Perf Quarter	-9.73%
Sales	31.77M	P/S	0.22	EPS this Y	-	Inst Trans	-	Short Ratio	4.31	Perf Half Y	-7.73%
Book/sh	2.53	P/B	0.66	EPS next Y	-	ROA	-49.45%	Short Interest	0.06M	Perf Year	-62.05%
Cash/sh	4.57	P/C	0.37	EPS next 5Y	20.00%	ROE	-108.94%	52W Range	1.26 - 6.40	Perf YTD	-4.02%
Dividend Est.	-	P/FCF	-	EPS past 5Y	66.28%	ROI	-123.11%	52W High	-73.91%	Beta	2.41
Dividend TTM	-	Quick Ratio	2.57	Sales past 5Y	124.62%	Gross Margin	12.99%	52W Low	32.54%	ATR (14)	0.20
Dividend Ex-Date	-	Current Ratio	2.66	EPS Y/Y TTM	23.38%	Oper. Margin	-46.37%	RSI (14)	43.81	Volatility	13.98% 10.87%
Employees	337	Debt/Eq	1.15	Sales Y/Y TTM	-18.44%	Profit Margin	-77.88%	Recom	1.00	Target Price	7.00
Option/Short	No / Yes	LT Debt/Eq	0.90	EPS Q/Q	54.57%	Payout	-	Rel Volume	0.22	Prev Close	1.66
Sales Surprise	1.23%	EPS Surprise	0.00%	Sales Q/Q	23.55%	Earnings	Apr 16 AMC	Avg Volume	14.80K	Price	1.67
SMA20	-8.94%	SMA50	-3.79%	SMA200	-13.25%	Trades		Volume	3,223	Change	0.60%

Jun-17-24 08:00AM	XWELL Opens New XpresSpa Location at Philadelphia International Airport (GlobeNewswire) -6.75%
Jun-05-24 08:00AM	XWELL Introduces New Esthetic Facial Services to Naples Wax Center Locations (GlobeNewswire)
May-23-24 08:00AM	XWELL Continues to Innovate in Airport Wellness Space with New Massage Solutions: Introducing Ceragem V6 in select XpresSpa Locations in US (GlobeNewswire)
May-15-24 11:52PM	XWEL Stock Earnings: XWELL Reported Results for Q1 2024 (InvestorPlace)
04:30PM	XWELL, Inc. Reports First Quarter 2024 Results (GlobeNewswire)
08:00AM	Loading…
May-02-24 08:00AM	XpresSpa Introduces IV Hydration Drip Therapy at Miami International Airport (GlobeNewswire)
Apr-19-24 09:00AM	XWELL Inc (XWEL) Q4 2023 Earnings Call Transcript Highlights: Strategic Expansions and Cost ... (GuruFocus.com)
Apr-17-24 08:48AM	XWELL, Inc. (NASDAQ:XWEL) Q4 2023 Earnings Call Transcript (Insider Monkey)
Apr-16-24 11:52PM	XWEL Stock Earnings: XWELL Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:30PM	XWELL, Inc. Reports Fiscal Year 2023 Results (GlobeNewswire)
08:00AM	XWELL, Inc. to Report Fiscal Year 2023 Financial Results on Tuesday, April 16, 2024 (GlobeNewswire)
Apr-01-24 04:30PM	XWELL, Inc. Plans to File Form 12b-25 to Extend Filing Date of its Form 10-K (GlobeNewswire) -11.38%
Mar-12-24 07:01AM	CDC Traveler-based Genomic Surveillance Program to Expand to Two New US International Airports in Miami and Chicago (PR Newswire)
Feb-14-24 08:00AM	XWELL Advances Expansion Plan Outside the Airport with Three New Naples Wax and Skin Care Locations (GlobeNewswire) +11.18%
Jan-04-24 08:00AM	XWELL Announces Plans to Open an XpresSpa in THE PENN DISTRICT (GlobeNewswire)
04:15PM	Loading…
Dec-15-23 04:15PM	XWELL Appoints Veteran Consumer & Wellness Entrepreneur Ga lle Wizenberg to its Board of Directors (GlobeNewswire)
Dec-11-23 08:00AM	XpresSpa Introduces Clockwork Robotic Manicures at Harry Reid International Airport in Las Vegas (GlobeNewswire)
Nov-15-23 08:00AM	XWELL Opens New XpresSpa Location in Abu Dhabi International Airport (GlobeNewswire)
Nov-14-23 04:30PM	XWELL, Inc. Reports Third Quarter 2023 Results (GlobeNewswire) +5.93%
Nov-06-23 07:06AM	US CDC to expand surveillance of travelers for respiratory viruses (Reuters)
07:00AM	Ginkgo Bioworks and XWELL Implement Expanded CDC Traveler-based Genomic Surveillance Program to Test for More than 30 Known Pathogens (PR Newswire)
Oct-11-23 08:00AM	XWELL Unveils New Corporate Identity and Enhanced Website for its Leading Airport Spa Brand, Xpres Spa (GlobeNewswire) -6.47%
Oct-09-23 08:00AM	XWELL's CEO Scott Milford Discusses Strategic Growth Plans During Recent Investor Fireside Chat (GlobeNewswire)
Oct-02-23 08:00AM	XWELL Celebrates Breast Cancer Awareness Month with Philanthropic Nail Care Program (GlobeNewswire)
Sep-28-23 09:00AM	XWELL s CEO Scheduled to Present at Upcoming Investor Fireside Chat on October 4, 2023 (GlobeNewswire) -10.77%
Sep-27-23 08:00AM	XWELL, Inc. Announces 1-for-20 Reverse Stock Split (GlobeNewswire) -25.40%
Sep-19-23 08:00AM	XWELL Introduces New Stretch Service at XpresSpa (GlobeNewswire)
Sep-12-23 04:30PM	XWELL Grows Footprint Outside the Airport with Acquisition of Naples Wax Center (GlobeNewswire) +8.43%
Aug-19-23 08:02AM	XWELL, Inc. (NASDAQ:XWEL) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-17-23 08:08AM	XWELL Extends Collaboration with Centers for Disease Control and Preventions Traveler-Based Genomic Surveillance Program (GlobeNewswire)
06:23AM	Loading…
Aug-15-23 06:23AM	Q2 2023 XWELL Inc Earnings Call (Thomson Reuters StreetEvents) -10.87%
Aug-14-23 04:30PM	XWELL, Inc. Reports Second Quarter 2023 Results (GlobeNewswire)
Aug-07-23 04:30PM	XWELL, Inc. to Announce Second Quarter 2023 Financial Results on Monday, August 14 (GlobeNewswire)
Jul-20-23 08:00AM	XpresSpa Debuts Clockwork Robotic Manicures at Miami International Airport (GlobeNewswire)
Jul-18-23 04:15PM	XWELL Unveils XWELL Rewards Loyalty Program (GlobeNewswire) +18.32%
Jul-14-23 11:22AM	Here's Why We're A Bit Worried About XWELL's (NASDAQ:XWEL) Cash Burn Situation (Simply Wall St.) -5.56%
Jul-13-23 08:00AM	XWELL, Inc. Appoints Suzanne Scrabis as Chief Financial Officer (GlobeNewswire) +12.50%
May-16-23 05:54AM	Q1 2023 XWELL Inc Earnings Call (Thomson Reuters StreetEvents)
May-15-23 04:30PM	XWELL, Inc. Reports First Quarter 2023 Results (GlobeNewswire)
May-11-23 12:39PM	Hey Redditors! Its Time to Dump MULN Stock Before It Falls Below $1. (InvestorPlace)
08:00AM	XWELL, Inc. to Announce First Quarter 2023 Financial Results on Monday, May 15 (GlobeNewswire)
May-04-23 08:00AM	XWELL, Inc. Names Valerie Lightfoot Chief Financial Officer (GlobeNewswire) +9.01%
May-03-23 08:00AM	XWELL Unveils Automated Massage Chairs at XpresSpa Locations Across the U.S. (GlobeNewswire)
Apr-27-23 04:15PM	XWELL, Inc. Granted 180-Day Extension by NASDAQ to Regain Compliance with Minimum Bid Price Rule (GlobeNewswire) -10.45%
Apr-19-23 03:54PM	Revenues Working Against XWELL, Inc.'s (NASDAQ:XWEL) Share Price (Simply Wall St.)
Apr-18-23 06:35AM	Q4 2022 XWELL Inc Earnings Call (Thomson Reuters StreetEvents) -7.93%
Apr-17-23 04:15PM	XWELL, Inc. Reports Fiscal Year 2022 Results (GlobeNewswire) +5.22%
Apr-14-23 05:05PM	XWELL, Inc. to Announce 2022 Financial Results on Monday April 17 (GlobeNewswire)
Mar-30-23 04:30PM	XWELL Announces Plans to File Form 12b-25 to Extend Filing Date of its Form 10-K And Provides Preliminary FY2022 Operating Update (GlobeNewswire)
Mar-22-23 08:00AM	First Robot Manicure Unveiled at XpresSpa at John F. Kennedy International Airport (GlobeNewswire)
Jan-31-23 08:00AM	XWELL to Participate in Water Tower Fireside Chat Series (GlobeNewswire)
Jan-17-23 08:00AM	Ginkgo Bioworks and XpresCheck Expand CDCs Traveler-Based Genomic Surveillance Program to Detect Influenza Variants (GlobeNewswire)
Dec-20-22 09:11AM	12 Penny Stocks With Biggest Upside (Insider Monkey)
Dec-12-22 08:00AM	XWELL Chief Executive Officer Issues Letter to Shareholders Regarding the Companys Operating Strategy (GlobeNewswire)
Dec-05-22 08:00AM	XWELL to Bring State of the Art Technology to XpresSpa and Treat Locations in Partnership with HydroMassage® and Human Touch® (GlobeNewswire)
Nov-16-22 05:20AM	XWELL Third Quarter 2022 Earnings: US$0.076 loss per share (vs US$0.053 profit in 3Q 2021) (Simply Wall St.) -9.60%
Nov-10-22 04:00PM	XWELL, Inc. Reports Third Quarter 2022 Results (GlobeNewswire)
Nov-09-22 08:00AM	XWELL Increases International Footprint with Five New XpresSpa Locations at Istanbul International Airport (GlobeNewswire) -5.22%
Nov-07-22 08:00AM	XWELL to Bring Robotic Manicures to US Airports Through New Partnership with Clockwork (GlobeNewswire) -6.61%
Nov-03-22 06:00PM	XWELL, Inc. to Announce Third Quarter 2022 Financial Results on Thursday, November 10 (GlobeNewswire)
Nov-02-22 04:00PM	XWELL Celebrates Opening of New Treat Location at Salt Lake City International Airport (GlobeNewswire)

XWELL, Inc. provides global travel health and wellness services. It operates through the following segments: XpresSpa, XpresTest, Naples Wax Center, Treat, and Corporate & Other. The XpresSpa segment offers travelers premium spa services, including massage, nail and skin care, as well as spa and travel products. The XpresTest segment deals with diagnostic COVID-19 tests at XpresCheck Wellness Centers in airports, to airport employees and to the traveling public. The Naples Wax Center segment is focused on the products and service offerings from face and body waxing to a range of skincare and cosmetic products. The Treat segment is a wellness brand that provides access to wellness services for travelers at on-site centers. The company was founded by Jonathan Medved and David Goldfarb on January 9, 2006 and is headquartered in New York, NY.

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

WRAP

Wrap Technologies Inc

PTPI

Petros Pharmaceuticals Inc

SNPX

Synaptogenix Inc

XWEL

XWELL Inc

Upgrade your FINVIZ experience